| Document |
Document Title |
|
WO/2003/084820A2 |
The invention relates to packages, packing materials and to bag-in-packages for packing products which can be spoiled by microbes, mainly food products and to methods for protecting said products against microbial spoilage when using sai...
|
|
WO/2003/079984A2 |
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...
|
|
WO/2003/074495A1 |
Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseas...
|
|
WO/2003/071884A1 |
The invention relates to a compound containing creatine, an acid component and/or a complexing agent. The invention also relates to methods for producing said compound, to a formulation containing the same, and to the use of the inventiv...
|
|
WO/2003/068209A1 |
Metformin salts of lipophilic acids, their pharmaceutical formulations, and methods of administrating the metformin salts for the treatment of hyperglycemia.
|
|
WO/2003/066673A1 |
The invention relates to new basic amino acid derivatives of general formulae I, II and III, and the preparation and use thereof in treatment of pain. The compounds have histogranin-like antinociceptive, morphine potentiating and COX-2 i...
|
|
WO/2003/063797A2 |
Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating dela...
|
|
WO/2003/057164A2 |
Lipids and compositions of lipids that can be used as lipid aggregates (i.e., liposomes) for the delivery of macromolecules and other compounds into cells are provided. The lipids have a general structure represented by formula (I). The ...
|
|
WO/2003/057169A2 |
The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infect...
|
|
WO/2003/055603A1 |
The invention relates to a method for separating and recycling catalyst components of a chemical reaction mixture involving oxidative direct carbonylation.
|
|
WO/2003/055849A1 |
The invention relates to a method for the production of solutions a quaternary cation and an anion from a deprotonated hydroxy aromatic in an organic solvent by a reactive extraction of a quaternary salt in the presence of an aqueous hyd...
|
|
WO/2003/053915A2 |
This invention relates to compounds of the Formula (I):(Chemical formula should be inserted here as it appears on abstract in paper form)(I)or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the tre...
|
|
WO/2003/053917A1 |
Novel guanidine compounds represented by the general formulae [I-1], [I-2], and [I-3], and pest controllers containing the same as the active ingredient.
|
|
WO/2003/051357A1 |
Novel compounds of formula (I), which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment of any disea...
|
|
WO/2003/048116A2 |
The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their phar...
|
|
WO/2003/048106A2 |
The invention concerns 1,3-diarylprop-2-en-1-ones and derivatives, compositions containing same and the use thereof. The invention concerns in particular novel substituted 1,3-diarylprop-2-en-1-ones having a therapeutic activity for use ...
|
|
WO/2003/042237A1 |
A peptide derivative represented by the general formula (I): (I) wherein X represents −CH(OH)− or −CO−&semi R1 represents hydrogen or an amino−protecting group&semi R2 represents hydroxy or lower alkoxy&semi one of R3 and R4 re...
|
|
WO/2003/037865A1 |
The present invention relates to compounds of formula (I): (I) their pharmacologically acceptable salts, or solvates and hydrates, and their prodrugs, respectively, and to pharmaceutical compositions containing the same as active ingredi...
|
|
WO/2003/033437A2 |
The present invention relates to compounds according to the formula (I) (I) A further object of the invention is a method of forming a library of components which are potentially capable of binding to neuraminidase, in particular influen...
|
|
WO/2003/034071A2 |
The present invention relates to a method of forming a library of components which are potentially capable of binding to a target, which method comprises i) selecting a plurality of molecules carrying a functionality which may interact w...
|
|
WO/2003/029265A1 |
A novel substance inosine&sol L−arginine salt and a cell activator or a plant growth promoter prepared by dissolving the salt in water. These agents are inosine preparations which can be distributed as a solid product and quickly disso...
|
|
WO/2003/029198A1 |
The invention relates to the use of compounds having general formula X-(A)¿n?-Y, wherein: n varies between 6 and 20; X denotes a hydrogen atom, an R¿a?CO, R¿a?OCO, R¿a?NHCO or R¿a?SO¿2? group, R¿a? being an alkyl, alkenyl, alkynyl...
|
|
WO/2003/029201A1 |
The invention relates to compositions and methods for treating or preventing disease or disorders caused by or associated with certain bacterial infection, especially $i(Escherichia coli (E. coli)) or $i(Helicobacter pylori (H. pylori)) ...
|
|
WO/2003/024945A2 |
The invention relates to a simple, cost-effective method for producing polyphosphates of organic bases. According to said method, a mixture of phosphorus pentaoxide and at least one organic nitrogen base is reacted with at least one comp...
|
|
WO/2003/024920A1 |
The current invention provide novel compounds, methods of treating preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological di...
|
|
WO/2003/024921A1 |
The current invention provides compounds of the general formula (I), methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, can...
|
|
WO/2003/024407A2 |
The present invention features compounds useful for inhibiting Rnase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including ...
|
|
WO/2003/022795A1 |
The invention relates to $g(b)-alanine amides of general formula (I), wherein: R?1¿ represents hydrogen or C¿1-6? alkyl that is optionally substituted by hydroxy, amino, carboxy, carbamoyl, methylmercapto, guanidino, optionally substit...
|
|
WO/2003/014076A2 |
Synthesis routes that can be adapted to large scale synthesis of oligoguanidine compounds such as oligoarginine compounds are described which use a perguanidinylation step to convert a group of $g(v)-amino groups to the corresponding gua...
|
|
WO/2003/006628A2 |
Disclosed are compounds that inhibit the microbial NAD synthetase enzyme. For example, disclosed are compounds of the formula Ar¿1?-X-Ar¿2?-Y-L-Z-Q, wherein Q is Q¿1?Ar¿3? or Ar¿3?Q¿1?; Ar¿1?, Ar¿2?, and Ar¿3? are independently ...
|
|
WO/2003/000643A1 |
Nitrooxyderivative compounds or salts thereof having the following general formula (I): A-(B)¿b0?-(C)¿co?-NO¿2? (I) wherein: c0 is an integer and is 0 or 1, b0 is an integer and is 0 or 1, A = R-T¿1?-, wherein R is the radical of for...
|
|
WO2001085095B1 |
The invention relates to the new arginine salt forms of S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-met
hyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations...
|
|
WO/2002/092555A1 |
The invention relates to compounds which are useful as orally administrable drugs (particularly, therapeutic or preventive agents for influenza) having sialidase−inhibiting activity and the guanidino groups of which are protected with ...
|
|
WO/2002/085844A1 |
The present invention releates to certain novel guanidine or amidine acid derivatives and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for th...
|
|
WO/2002/085838A1 |
The present invention relaters to copper-catalyzed carbon-heteroatom and carbon-carbon bond-forming methods. In certain embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-nitrogen bond between the ...
|
|
WO/2002/081483A2 |
The present invention provides compounds with activity as inhibitors of acyl glucosaminylinositol amidases with amidase activity against S-conjugate amides, particularly mycothiol-derived S-conjugate amides. Certain of the invention comp...
|
|
WO2001072685A9 |
Novel cytotoxic polyamine analogues are disclosed. These analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit cell growth and/or proliferation, for example cancer and post-angioplasty injury.
|
|
WO/2002/076965A1 |
The invention relates to novel non peptide compounds (mimetics) based on a thrombin receptor sequence and novel methods for the synthesis of these compounds. These compounds act as agonists or antagonists in a variety of cells including ...
|
|
WO/2002/076963A1 |
The invention relates to compounds of general formula (I), in which A, X, Y and R1 are defined in Claim 1. These compounds may be used in the treatment of pathologies associated with insulin resistane syndrome.
|
|
WO/2002/076931A1 |
A novel salt, creatine taurinate, and the compositions containing same (health foods, dietary supplements or drugs) are disclosed.
|
|
WO/2002/072068A2 |
This invention pertains to certain lipids and lipid compositions, liposomes and lipoplexes formed therefrom, methods for their synthesis and preparation, compositions and medicaments comprising such liposomes and lipoplexes, and methods ...
|
|
WO/2002/070468A2 |
Compounds which can be represented by the general formula (I) and in which A is selected independently from the carboxamide group, the thiocarboxamide group, and the carbonyl group, -R¿1? is selected from an alkyl group having from 1 to...
|
|
WO/2002/068381A2 |
Compounds, compositions and methods treating arthritic disorders such as osteoarthritis or rheumatoid arthritis, and for treating other diseases associated with altered mitochondrial function, such as cancer, psoriasis, stroke, Alzheimer...
|
|
WO/2002/068377A1 |
(R) -2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treat...
|
|
WO/2002/066421A1 |
Molecules of the general formula (I) without intramolecular peptidic bonds, able to mimic the RGD peptide, containing ARG-GLY-ASP motif 'arginine-glycine-aspartic acid' (that is a potent inhibitor, in vivo and in vitro, of cellular adhes...
|
|
WO/2002/064136A2 |
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases m...
|
|
WO/2002/062762A2 |
Compounds of formula (I) are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
|
|
WO/2002/058690A2 |
The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration ...
|
|
WO/2002/053090A2 |
The invention concerns a medicinal combination, for treating diabetes, in particular type 2 diabetes, associating a biguanine, in particular a N-dimethylbiguanine, as first medicine, and a carrier agent for said biguanine, as second medi...
|
|
WO/2002/052957A1 |
The invention relates to addition and/or co-ordination compounds consisting of creatine and citric acid in the ratio of >1.0 to 3.0: 1.0. Said compounds are characterised in that they have (KBr) bands in the IR spectrum, where $g(n)= 342...
|
